Mikhail Blagosklonny currently serves as a professor of Oncology at the Roswell Park Cancer Institute which is located in Buffalo, New York. He has dedicated his career to the research and education solutions of cancer and its ultimate therapies. Working as the editor in chief of Oncotarget, he established and published research that was conducted through an extensive process solely based on the role of aging. He is a widely known supporter to Rapamycin, which is a cancer drug used on patients to prolong their life and increase their quality of life. Rapamycin, which is also known as Sirolimus, is used to help treat and prevent organ transplant rejection. It has also been used for coronary stents and for the use of treatment via rare forms of lung diseases. Samples were utilized for the very first time in 1972 when it was originally used as an anti-fungal agent. Additionally, the therapeutic benefits were brought to light with a valid response to improve the overall aging process. The drug is no longer used as an anti-fungal agent.
There are many reasons why physicians and medical staff all over the world believe that Rapamycin is one of the best medicines they’ve ever encountered. The countless positive effects that the drug has on patients are remarkable and are very valuable to many. Rapamycin has many immunosuppressant properties which help the body accept an organ transplant easier than ever. Rapamycin has an overall lower level of toxicity in relation to the kidneys in comparison to other anti-rejection medications. It is also known for treating patients with rare diseases such as hemolytic-uremic syndrome. Hemolytic-uremic syndrome is a combination of anemia, kidney failure and an increasingly low platelet count. These issues lead to renal failure, which creates many other issues. Studies have shown that Rapamycin’s treatment is positive for treating those who suffer from the rare condition. Rapamycin is also known for treating Lymphangioleiomyomatosis (LAM), coronary stent coating and cancer. When it’s taken in the proper doses, it can become very effective in enhancing the immune systems and helping to reduce the overall risk of cancer. The benefits of Rapamycin are endless, and they continually increase with research, education and time spent discovering the benefits. There are also many different research methods in progress such as to how much it increases longevity in life, treatment of Alzheimer’s disease and Muscular Dystrophy.
Mikhail Blagosklonny has been studying the positive effects of Rapamycin for many years, and his findings are astounding. He is a well-known professor and philanthropist who works to help patient’s experience the best possible treatment available. His extensive skills and research help him focus on the relationship between cancer and aging. His ultimate goals is to conduct high levels of research that will help him find the best solution to help treat cancer and prolong the lives of many individuals. He also hopes to be able to find a way that he can help those recover quickly after cancer by repairing the cells that are damaged in the process.